Terrain Biosciences, Cambridge, MA-based RNA design-build company, raised $9M in Seed funding.
Backers included Magnetic Ventures, Bruker Corporation, Josef Feldman, John Maraganore, Hans Bishop, and John Evans.
The company intends to use the funds to bring research in RNA design and manufacturing to innovators building RNA-based therapies and vaccines, and support development of personalized cancer vaccines.
Founded by Omar Abudayyeh and Jonathan Gootenberg and Patrick Hsu, and led by CEO Chetan Tadvalkar, Terrain Bio helps RNA therapeutics companies design and build RNA, faster.
Leveraging the latest innovations in protein and RNA design and the deep expertise of its scientific cofounders, it brings speed and quality to RNA manufacturing. High-quality RNA enables the generation of experimental data that trains novel machine-learning models for RNA sequence design, creating a sandbox for scientists to design and build their own sequences. Through a catalog of commonly used sequences, custom RNA build, and AI-guided sequence design tools, drug developers gain access to a wealth of resources for every step of the journey to the clinic and beyond, with confidence that their sequences will be optimized for safety, efficacy, and manufacturability.
FinSMEs
14/02/2025